Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

Haemophilia

Volumn 8, Issue 3, 2002, Pages 273-279

  Lacroix Desmazes, S ^a   Misra, N ^a   Bayry, J ^a   Artaud, C ^a   Drayton, B ^a   Kaveri, S V ^a   Kazatchkine, M D ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Factor VIII; FVIII inhibitor; Haemophilia; Idiotype

Indexed keywords

ADENOVIRUS VECTOR; ALLOANTIBODY; ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CD4 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NEUTRALIZING ANTIBODY; PROTHROMBIN COMPLEX; RETROVIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE THERAPY; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; IMMUNITY; IMMUNOLOGY; REVIEW;

AUTOANTIBODIES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNITY; ISOANTIBODIES;

EID: 0036588775     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00624.x     Document Type: Article

References (57)

1. Kasper CK, Aledort LM, Counts RB. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
2. Kessler CM. An introduction to FVIII inhibitors: the detection and quantitation. Am J Med 1991; 91: 1S-5S.
3. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for Factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
4. Schwaab R, Brackmann H-H, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
5. Algiman M, Dietrich G, Nydegger U, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992; 89: 3795-9.
6. Fulcher CA, De Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-32.
7. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-505.
8. Scandella D, De Graaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6.
9. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
10. Fulcher CA. Immunochemistry of factor VIII:C inhibitor antibodies. Am J Med 1991; 91: 6S-8S.
11. Fulcher CA, Lechner K, de Graaf Mahoney S. Immunoblot analysis shows changes in FVIII inhibitor chain specificity in FVIII inhibitor patients over time. Blood 1988; 72: 1348-56.
12. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993; 14: 203-8.
13. Miller SD, McRae BL, Vanderlugt CL et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol Rev 1995; 144: 225-44.
14. Moreau A, Lacroix-Desmazes S, Stieltjes N et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity, are present in the plasma of non-responder patients with severe hemophilia A and healthy blood donors. Blood 2000; 95: 3435-41.
15. Hultin MB. Acquired inhibitors in malignant and nonmalignant diseases states. Am J Med 1991; 91: 9S-13S.
16. Gilles JGG, Lavend'homme R, Jacquemin MG, Peerlinck K, Vermylen J, Saint-Remy JMR. Anti-factor VIII antibodies belonging to the IgA1 isotype in a mild hemophilia A patient. In: Lee CA, Kessler CM, eds. XXIII International Congress, Vol. 4. Oxford: Blackwell Science. 1998: 234.
17. Shapiro S. The immunologic character of acquired inhibitors of antihemophiliac globulin (Factor VIII) and the kinetics of their interaction with FVIII. J Clin Invest 1967; 46: 147-56.
18. Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sanguinis 1996; 70 (Suppl. 1): 9-14.
19. Biggs R, Austen DE, Denson KW, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. Br J Haematol 1972; 23: 137-55.
20. Biggs R, Austen DE, Denson KW, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol 1972; 23: 125-35.
21. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-42.
22. Jacquemin MG, Desqueper BG, Benhida A et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
23. Jacquemin M, Benhida A, Peerlinck K et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000; 95: 156-63.
24. van Den Brink EN, Turenhout EA, Davies J et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood 2000; 95: 558-63.
25. van den Brink E, Turenhout E, Bank C, Fijnvandraat K, Peters M, Voorberg J. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood 2000; 96: 540-5.
26. van den Brink E, Turenhout E, Bovenschen N et al. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VII. Blood 2001; 97: 966-72.
27. Reding M, Wu H, Krampf M et al. Sensitization of CD4+ T cells to coagulation factor VIII. Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
28. Wu H, Reding M, Diethelm-Okita B et al. 1998 Identification of FVIII-reactive CD4+ T cells in normal individuals. In: Lee CA, Kessler CM, eds. XXIII International Congress, Vol. 4. Oxford: Blackwell Science. 1998: 236.
29. Ewenstein B, Hoots W, Lusher J et al. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85: 35-9.
30. Qian J, Borokov M, Bi L, Kazazian HH, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
31. Qian J, Burkly L, Smith E et al. Role of CD154 in the secondary immune response: the reduction of preexisting splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
32. Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human antifactor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 1992; 67: 665-71.
33. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
34. Lollar P, Parker E, Curtis J et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 1994; 93: 2497-504.
35. Scandella D, Mattingly M, Prescott R. A recombinant Factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993; 82: 1767-75.
36. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-5.
37. Scandella D, Gilbert GE, Shima M et al. Some Factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
38. Shima M, Fulcher CA, De Graaf Mahoney S, Houghten RA, Zimmerman TS. Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669. J Biol Chem 1988; 263: 10198-203.
39. Foster PA, Fulcher CA, Huoghten RA, de Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-FVIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-8.
40. Lubahn BC, Ware J, Stafford DW, Reisner HM. Identification of a FVIII epitope recognized by a human hemophilic inhibitor. Blood 1989; 73: 497-9.
41. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to Factor IX. Blood 1998; 92: 136-42.
42. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-84.
43. Shima M, Scandella D, Yoshioka A et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
44. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for FVIII inhibition. J Biol Chem 1996; 271: 27424-31.
45. Lacroix-Desmazes S, Moreau A, Sooryanarayana et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5: 1044-7.
46. Lacroix-Desmazes S, Bayry J, Misra N et al. High prevalence of antibodies with proteolytic activity to Factor VIII in hemophilia A patients with Factor VIII inhibitors. New Eng J Med 2002; 846: 662-7.
47. Kazatchkine MD, Sultan Y, Burton-Kee EJ, Mowbray JF. Circulating immune complexes containing anti-FVIII antibodies in multitransfused patients with haemophilia A. Clin Exp Immunol 1980; 39: 315-20.
48. Nilsson IM, Berntorp E, Zettervall O, Dahlback B. Noncoagulation inhibitory Factor VIII antibodies after induction of tolerance to Factor VIII in hemophilia A. Blood 1990; 75: 378-83.
49. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-31.
50. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to Factor VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74: 311-6.
51. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to Factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; ii: 765-8.
52. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992; 79: 2946-51.
53. VandenDriessche T, Vanslembrouck V, Goovaerts I et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII- deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379-84.
54. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia: principal results from the international registry. Thromb Haemost 1994; 72: 155-8.
55. Kazatchkine MD, Lacroix-Desmazes S, Moreau A, Kaveri SV. Idiotypic regulation of anti-factor VIII antibodies. Haematologica 2000; 85: 97-9.
56. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
57. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.